ESMO 2025 – Datroway and Trodelvy face off in triple-negative breast
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
And Treeline and HengRui also get in on the pan-RAS act.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
NT-125 is discontinued, while two key Datroway readouts are delayed.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.